Stock Scorecard

Stock Summary for Pasithea Therapeutics Corp - Warrants (11/08/2026) (KTTAW) - $0.01 as of 1/10/2026 2:15:02 AM EST

Total Score

11 out of 30

Safety Score

5 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for KTTAW

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for KTTAW

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for KTTAW

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for KTTAW

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for KTTAW (5 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for KTTAW

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock 12/3/2025 5:31:00 AM
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock 12/1/2025 5:31:00 AM
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data 11/27/2025 2:11:00 AM
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients 11/21/2025 8:35:00 PM
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients 11/4/2025 3:03:00 PM

Financial Details for KTTAW

Company Overview
Ticker KTTAW
Company Name Pasithea Therapeutics Corp - Warrants (11/08/2026)
Country N/A
Description Pasithea Therapeutics Corp. (KTTAW) is a Miami Beach-based biopharmaceutical company specializing in the development of innovative therapies targeting central nervous system disorders and mental health conditions. Utilizing its proprietary research platform, Pasithea is committed to advancing novel therapeutic candidates that fulfill significant unmet medical needs in neuroscience. With a robust pipeline and a focus on improving patient outcomes, the company aims to position itself as a leader in the rapidly evolving mental health therapeutic landscape, offering unique solutions to complex health challenges.
Sector Name N/A
Industry Name N/A
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 0.01
Price 4 Years Ago 0.03
Last Day Price Updated 1/10/2026 2:15:02 AM EST
Last Day Volume 1,522
Average Daily Volume 87,736
52-Week High 0.12
52-Week Low 0.01
Last Price to 52 Week Low 0.00%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE 0.00
Free Cash Flow Ratio 0.00
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 4.02
Total Cash Per Share 4,872.98
Book Value Per Share Most Recent Quarter 1.64
Price to Book Ratio 0.00
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 0
Market Capitalization 0
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 12.89%
Reported EPS 12 Trailing Months 0.00
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.00
Net Income Twelve Trailing Months -13,494,476
Net Income Past Year -13,904,584
Net Income Prior Year -15,961,658
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 468.36%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 4,122,953
Total Cash Past Year 6,922,729
Total Cash Prior Year 16,331,052
Net Cash Position Most Recent Quarter 4,122,953
Net Cash Position Past Year 6,922,729
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 14,782,676
Total Stockholder Equity Prior Year 23,398,452
Total Stockholder Equity Most Recent Quarter 12,206,682

Free Cash Flow
Free Cash Flow Twelve Trailing Months -12,257,720
Free Cash Flow Per Share Twelve Trailing Months 0.00
Free Cash Flow Past Year -13,923,440
Free Cash Flow Prior Year -13,459,712

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.02
20-Day Bollinger Upper Band 0.04
Beta 0.22
RSI 42.03
50-Day SMA 0.02
150-Day SMA 0.00
200-Day SMA 0.04

System
Modified 1/14/2026 12:08:23 AM EST